Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AVTX Avalo Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AVTX
Price (delayed)
$3.68
Market cap
$39.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.01
Enterprise value
-$85.26M
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of
Highlights
AVTX's net income has soared by 151% YoY
The EPS has soared by 98% YoY and by 49% from the previous quarter
Avalo Therapeutics's gross margin has soared by 199% YoY but it has decreased by 10% from the previous quarter
AVTX's revenue has shrunk by 70% YoY
The company's gross profit fell by 10% QoQ and by 9% YoY
Key stats
What are the main financial stats of AVTX
Market
Valuations
Earnings
Shares outstanding
10.83M
Market cap
$39.85M
Enterprise value
-$85.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.32
Price to sales (P/S)
87.74
EV/EBIT
-1.22
EV/EBITDA
-1.21
EV/Sales
-193.34
Revenue
$441,000
Gross profit
$725,000
Operating income
-$50.42M
Net income
$73.01M
EBIT
$69.91M
EBITDA
$70.18M
Free cash flow
-$52.31M
Per share
Balance sheet
Liquidity
EPS
-$4.01
EPS diluted
-$16.43
Free cash flow per share
-$4.97
Book value per share
$11.49
Revenue per share
$0.04
TBVPS
$12.18
Total assets
$138.52M
Total liabilities
$15.91M
Debt
$0
Equity
$122.62M
Working capital
$121.33M
Debt to equity
0
Current ratio
22.61
Quick ratio
22.28
Net debt/EBITDA
-1.78
Margins
Efficiency
Dividend
EBITDA margin
15,913.4%
Gross margin
164.4%
Net margin
16,556%
Operating margin
-11,432.2%
Return on assets
58.9%
Return on equity
111%
Return on invested capital
N/A
Return on capital employed
52.6%
Return on sales
15,852.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTX stock price
How has the Avalo Therapeutics stock price performed over time
Intraday
-8%
1 week
-23.01%
1 month
-24.9%
1 year
-65.99%
YTD
-50.47%
QTD
-54.06%
Financial performance
How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$441,000
Gross profit
$725,000
Operating income
-$50.42M
Net income
$73.01M
Gross margin
164.4%
Net margin
16,556%
Avalo Therapeutics's gross margin has soared by 199% YoY but it has decreased by 10% from the previous quarter
AVTX's net income has soared by 151% YoY
AVTX's revenue has shrunk by 70% YoY
AVTX's operating margin is up by 26% since the previous quarter
Price vs fundamentals
How does AVTX's price correlate with its fundamentals
Growth
What is Avalo Therapeutics's growth rate over time
Valuation
What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
0.32
P/S
87.74
EV/EBIT
-1.22
EV/EBITDA
-1.21
EV/Sales
-193.34
The EPS has soared by 98% YoY and by 49% from the previous quarter
The equity has contracted by 8% from the previous quarter
The P/S is 149% higher than the 5-year quarterly average of 35.2 but 11% lower than the last 4 quarters average of 98.5
AVTX's revenue has shrunk by 70% YoY
Efficiency
How efficient is Avalo Therapeutics business performance
The ROE has soared by 122% since the previous quarter
Avalo Therapeutics's ROA has soared by 120% YoY
Dividends
What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTX.
Financial health
How did Avalo Therapeutics financials performed over time
AVTX's total liabilities has dropped by 93% year-on-year and by 10% since the previous quarter
Avalo Therapeutics's quick ratio has increased by 15% from the previous quarter
The debt is 100% smaller than the equity
The equity has contracted by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.